Agomelatine : its role in the management of major depressive disorder

Autores
Cardinali, Daniel Pedro; Vidal, María Florencia; Vigo, Daniel Eduardo
Año de publicación
2012
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Fil: Cardinali, Daniel P. Pontificia Universidad Católica Argentina. Facultad de Ciencias Médicas. Departamento de Docencia e Investigación; Argentina
Fil: Vidal, María Florencia. Pontificia Universidad Católica Argentina. Facultad de Ciencias Médicas. Departamento de Docencia e Investigación; Argentina
Fil: Vigo, Daniel E. Pontificia Universidad Católica Argentina. Facultad de Ciencias Médicas. Departamento de Docencia e Investigación; Argentina
Abstract: Circadian rhythm abnormalities, as shown by sleep/wake cycle disturbances, constitute one the most prevalent signs of depressive illness; advances or delays in the circadian phase are documented in patients with major depressive disorder (MDD), bipolar disorder, and seasonal affective disorder (SAD). The disturbances in the amplitude and phase of rhythm in melatonin secretion that occur in patients with depression resemble those seen in chronobiological disorders, thus suggesting a link between disturbed melatonin secretion and depressed mood. Based on this, agomelatine, the first MT1/MT2 melatonergic agonist displaying also 5-HT2C serotonergic antagonism, has been introduced as an antidepressant. Agomelatine has been shown to be effective in several animal models of depression and anxiety and it has beneficial effects in patients with MDD, bipolar disorder, or SAD. Among agomelatine’s characteristics are a rapid onset of action and a pronounced effectiveness for correcting circadian rhythm abnormalities and improving the sleep/wake cycle. Agomelatine also improves the 3 functional dimensions of depression—emotional, cognitive, and social—thus aiding in the full recovery of patients to a normal life
Fuente
Clinical medicine insights : psychiatry. 2012, 4
Materia
TRASTORNOS DE LA CONDUCTA
DEPRESION
AGOMELATINA
RECEPTORES DE MELATONINA
ANTIDEPRESIVOS
ANSIOLITICOS
RECEPTORES
RECEPTORES DE SEROTONINA
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/4.0/
Repositorio
Repositorio Institucional (UCA)
Institución
Pontificia Universidad Católica Argentina
OAI Identificador
oai:ucacris:123456789/1630
Acceder
id RIUCA_5c25a9ba190affce0b65bfdbc7efe18c
oai_identifier_str oai:ucacris:123456789/1630
network_acronym_str RIUCA
repository_id_str 2585
network_name_str Repositorio Institucional (UCA)
spelling Agomelatine : its role in the management of major depressive disorderCardinali, Daniel PedroVidal, María FlorenciaVigo, Daniel EduardoTRASTORNOS DE LA CONDUCTADEPRESIONAGOMELATINARECEPTORES DE MELATONINAANTIDEPRESIVOSANSIOLITICOSRECEPTORESRECEPTORES DE SEROTONINAFil: Cardinali, Daniel P. Pontificia Universidad Católica Argentina. Facultad de Ciencias Médicas. Departamento de Docencia e Investigación; ArgentinaFil: Vidal, María Florencia. Pontificia Universidad Católica Argentina. Facultad de Ciencias Médicas. Departamento de Docencia e Investigación; ArgentinaFil: Vigo, Daniel E. Pontificia Universidad Católica Argentina. Facultad de Ciencias Médicas. Departamento de Docencia e Investigación; ArgentinaAbstract: Circadian rhythm abnormalities, as shown by sleep/wake cycle disturbances, constitute one the most prevalent signs of depressive illness; advances or delays in the circadian phase are documented in patients with major depressive disorder (MDD), bipolar disorder, and seasonal affective disorder (SAD). The disturbances in the amplitude and phase of rhythm in melatonin secretion that occur in patients with depression resemble those seen in chronobiological disorders, thus suggesting a link between disturbed melatonin secretion and depressed mood. Based on this, agomelatine, the first MT1/MT2 melatonergic agonist displaying also 5-HT2C serotonergic antagonism, has been introduced as an antidepressant. Agomelatine has been shown to be effective in several animal models of depression and anxiety and it has beneficial effects in patients with MDD, bipolar disorder, or SAD. Among agomelatine’s characteristics are a rapid onset of action and a pronounced effectiveness for correcting circadian rhythm abnormalities and improving the sleep/wake cycle. Agomelatine also improves the 3 functional dimensions of depression—emotional, cognitive, and social—thus aiding in the full recovery of patients to a normal lifeLibertas Academica2012info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfhttps://repositorio.uca.edu.ar/handle/123456789/16301179-557310.4137/CMPsy.S7989Cardinali, D. P., Vidal, M. F., Vigo, D. E. Agomelatine : its role in the management of major depressive disorder [en línea]. Clinical medicine insights : psychiatry. 2012, 4. doi:10.4137/CMPsy.S7989. Disponible en: https://repositorio.uca.edu.ar/handle/123456789/1630Clinical medicine insights : psychiatry. 2012, 4reponame:Repositorio Institucional (UCA)instname:Pontificia Universidad Católica Argentinaengenginfo:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/4.0/2025-07-03T10:55:19Zoai:ucacris:123456789/1630instacron:UCAInstitucionalhttps://repositorio.uca.edu.ar/Universidad privadaNo correspondehttps://repositorio.uca.edu.ar/oaiclaudia_fernandez@uca.edu.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:25852025-07-03 10:55:20.018Repositorio Institucional (UCA) - Pontificia Universidad Católica Argentinafalse
dc.title.none.fl_str_mv Agomelatine : its role in the management of major depressive disorder
title Agomelatine : its role in the management of major depressive disorder
spellingShingle Agomelatine : its role in the management of major depressive disorder
Cardinali, Daniel Pedro
TRASTORNOS DE LA CONDUCTA
DEPRESION
AGOMELATINA
RECEPTORES DE MELATONINA
ANTIDEPRESIVOS
ANSIOLITICOS
RECEPTORES
RECEPTORES DE SEROTONINA
title_short Agomelatine : its role in the management of major depressive disorder
title_full Agomelatine : its role in the management of major depressive disorder
title_fullStr Agomelatine : its role in the management of major depressive disorder
title_full_unstemmed Agomelatine : its role in the management of major depressive disorder
title_sort Agomelatine : its role in the management of major depressive disorder
dc.creator.none.fl_str_mv Cardinali, Daniel Pedro
Vidal, María Florencia
Vigo, Daniel Eduardo
author Cardinali, Daniel Pedro
author_facet Cardinali, Daniel Pedro
Vidal, María Florencia
Vigo, Daniel Eduardo
author_role author
author2 Vidal, María Florencia
Vigo, Daniel Eduardo
author2_role author
author
dc.subject.none.fl_str_mv TRASTORNOS DE LA CONDUCTA
DEPRESION
AGOMELATINA
RECEPTORES DE MELATONINA
ANTIDEPRESIVOS
ANSIOLITICOS
RECEPTORES
RECEPTORES DE SEROTONINA
topic TRASTORNOS DE LA CONDUCTA
DEPRESION
AGOMELATINA
RECEPTORES DE MELATONINA
ANTIDEPRESIVOS
ANSIOLITICOS
RECEPTORES
RECEPTORES DE SEROTONINA
dc.description.none.fl_txt_mv Fil: Cardinali, Daniel P. Pontificia Universidad Católica Argentina. Facultad de Ciencias Médicas. Departamento de Docencia e Investigación; Argentina
Fil: Vidal, María Florencia. Pontificia Universidad Católica Argentina. Facultad de Ciencias Médicas. Departamento de Docencia e Investigación; Argentina
Fil: Vigo, Daniel E. Pontificia Universidad Católica Argentina. Facultad de Ciencias Médicas. Departamento de Docencia e Investigación; Argentina
Abstract: Circadian rhythm abnormalities, as shown by sleep/wake cycle disturbances, constitute one the most prevalent signs of depressive illness; advances or delays in the circadian phase are documented in patients with major depressive disorder (MDD), bipolar disorder, and seasonal affective disorder (SAD). The disturbances in the amplitude and phase of rhythm in melatonin secretion that occur in patients with depression resemble those seen in chronobiological disorders, thus suggesting a link between disturbed melatonin secretion and depressed mood. Based on this, agomelatine, the first MT1/MT2 melatonergic agonist displaying also 5-HT2C serotonergic antagonism, has been introduced as an antidepressant. Agomelatine has been shown to be effective in several animal models of depression and anxiety and it has beneficial effects in patients with MDD, bipolar disorder, or SAD. Among agomelatine’s characteristics are a rapid onset of action and a pronounced effectiveness for correcting circadian rhythm abnormalities and improving the sleep/wake cycle. Agomelatine also improves the 3 functional dimensions of depression—emotional, cognitive, and social—thus aiding in the full recovery of patients to a normal life
description Fil: Cardinali, Daniel P. Pontificia Universidad Católica Argentina. Facultad de Ciencias Médicas. Departamento de Docencia e Investigación; Argentina
publishDate 2012
dc.date.none.fl_str_mv 2012
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://repositorio.uca.edu.ar/handle/123456789/1630
1179-5573
10.4137/CMPsy.S7989
Cardinali, D. P., Vidal, M. F., Vigo, D. E. Agomelatine : its role in the management of major depressive disorder [en línea]. Clinical medicine insights : psychiatry. 2012, 4. doi:10.4137/CMPsy.S7989. Disponible en: https://repositorio.uca.edu.ar/handle/123456789/1630
url https://repositorio.uca.edu.ar/handle/123456789/1630
identifier_str_mv 1179-5573
10.4137/CMPsy.S7989
Cardinali, D. P., Vidal, M. F., Vigo, D. E. Agomelatine : its role in the management of major depressive disorder [en línea]. Clinical medicine insights : psychiatry. 2012, 4. doi:10.4137/CMPsy.S7989. Disponible en: https://repositorio.uca.edu.ar/handle/123456789/1630
dc.language.none.fl_str_mv eng
eng
language eng
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/4.0/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/4.0/
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Libertas Academica
publisher.none.fl_str_mv Libertas Academica
dc.source.none.fl_str_mv Clinical medicine insights : psychiatry. 2012, 4
reponame:Repositorio Institucional (UCA)
instname:Pontificia Universidad Católica Argentina
reponame_str Repositorio Institucional (UCA)
collection Repositorio Institucional (UCA)
instname_str Pontificia Universidad Católica Argentina
repository.name.fl_str_mv Repositorio Institucional (UCA) - Pontificia Universidad Católica Argentina
repository.mail.fl_str_mv claudia_fernandez@uca.edu.ar
_version_ 1836638330570145792
score 12.993085

Publicaciones similares